Foster Dykema Cabot & Partners’s CRISPR Therapeutics CRSP Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$476	Hold	10	–	–	﹤0.01%	317
2025 Q4	$524	Hold	10	–	–	﹤0.01%	323
2025 Q3	$648	Hold	10	–	–	﹤0.01%	409
2025 Q2	$486	Hold	10	–	–	﹤0.01%	334
2025 Q1	$340	Hold	10	–	–	﹤0.01%	331
2024 Q4	$394	Hold	10	–	–	﹤0.01%	368
2024 Q3	$470	Hold	10	–	–	﹤0.01%	496
2024 Q2	$540	Hold	10	–	–	﹤0.01%	312
2024 Q1	$682	Hold	10	–	–	﹤0.01%	309
2023 Q4	$626	Buy	+10	New	+$553	﹤0.01%	271

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Foster Dykema Cabot & Partners's CRSP Position: Q1 2026 in Review

Foster Dykema Cabot & Partners held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 10 shares worth $476. The position accounts for ﹤0.01% of the portfolio, ranked #317.

Foster Dykema Cabot & Partners first reported a position in CRSP in Q4 2023 and has held it in 10 quarters since. The position peaked at $682 in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Foster Dykema Cabot & Partners held 10 shares of CRISPR Therapeutics worth $476 as of Q1 2026.
Foster Dykema Cabot & Partners left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up ﹤0.01% of Foster Dykema Cabot & Partners's portfolio in Q1 2026, its #317 holding.
Foster Dykema Cabot & Partners first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 10 quarters since.
Foster Dykema Cabot & Partners's CRISPR Therapeutics position peaked at $682 in Q1 2024.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q1 2026, filed 14 May 2026.